Cirrhosis (scarring of the liver) can lead to varices (abnormally enlarged veins) developing in the lower gullet (food pipe) or stomach causing the varices to bleed. Variceal bleeding is a serious complication of liver cirrhosis. The currently accepted treatment for patients who bleed from varices is known as standard of care (SOC) and includes using an endoscope (a bendy tube incorporating light and a tiny video camera) to tie off an enlarged vein with a rubber ring (variceal banding) or ...

GO TO STUDY

Transplant recipients will be invited to enrol in this LTFU study after they have completed the End-Of-Study (Week 84) visit or withdrawn from the Phase I/IIa study (TX200-KT02). Transplant recipients who were administered TX200-TR101 in the TX200-KT02 study will then proceed to have 13.5 years of follow-up post-enrolment to this study (equating approximately to 13.75 years of follow up post-end of ‘parent’ KT02 study). Since these subjects will have completed the first 1.5 years of follow-up post-dosing with TX200-TR101 in ...

GO TO STUDY

A prospective,randomised,phase II platform trial for sequential evaluation of experimental treatments versus investigator choice standard therapy (ICT) for patients with relapsed or refractory follicular lymphoma (rrFL). There are three sequential treatment rounds; each has a control arm of ICT and an experimental novel treatment arm. Patients in Round 1 (R1) will be randomised using a 1:1 allocation ratio to receive either ICT or epcoritamab + lenalidomide (experimental treatment). Patients in Rounds 2 (R2) and 3 (R3) (experimental treatments yet to ...

GO TO STUDY

FARGO is a randomised,phase IIa,multi-centre,placebo-controlled,single-blind,parallel group trial investigating the activity of FMT in the treatment of patients with PSC. The primary objective is to determine the effect of FMT,administered via colonoscopy (single dose) and via enema (once weekly for seven weeks),on circulating ALP values measured at 48 weeks.

GO TO STUDY

Part 1a will consist of dose escalation using a statistical hybrid design to identify the MTD and/or RDE(s) of INCA033989 monotherapy in participants with MF or revised IPSET-thrombosis high-risk ET (TGA). After initial characterization of safety, PK, and pharmacodynamic effects of INCA033989 as monotherapy in TGA, dose escalation will start in TGB-MF SubOpt R, which encompasses participants with MF exhibiting suboptimal response to ruxolitinib. Participants enrolled in TGB-MF SubOpt R must be on a stable dose of ruxolitinib for at least 8 ...

GO TO STUDY

This is a non-interventional Post-authorisation Safety Study (PASS) that will collect data from 2 groups of patients: those treated with avacopan for active ANCA-associated vasculitis (AAV), and a second cohort treated with a cyclophosphamide or rituximab-based induction regimen without avacopan for active AAV. The study will be conducted in Germany and United Kingdom. Additional countries may be considered according to availability of avacopan and suitability for the study. The overall study duration is anticipated to be up to 7 years. The ...

GO TO STUDY

Head and neck squamous cell carcinoma (H&N SCC) incorporate tumours of varying areas of the upper aerodigestive tract,including the larynx,hypopharynx,nasopharynx,and oropharynx. H&N cancer is increasingly common in the UK,with rates increasing by 34% since the early 1990s. The rising prevalence of H&N cancer has been attributed to a rising rate in women,and the prevalence of the Human papilloma virus (HPV) in oropharyngeal cancer,which can account for up to 70% of cases. The survival in H&N cancer is highly variable,ranging from over ...

GO TO STUDY

Primary biliary cholangitis (PBC) is a rare liver disease. A number of treatments exist,which slow the rate that liver disease gets worse. However,at the moment,doctors have to wait for one treatment to fail before adding in a second. As a result,many people with PBC develop symptoms and some go on to need a liver transplant. The aim of the OPERA trial is to see if people who are newly/recently diagnosed with PBC have a better outcome if they receive two medicines ...

GO TO STUDY

GT005, a recombinant adeno-associated viral serotype 2 (AAV2) vector encoding for human complement factor I, is currently being developed as a potential gene therapy for GA secondary to AMD. Current regulatory guidelines [EMA 2009; EMA 2018; FDA 2020] recommend that participants enrolled in gene therapy clinical trials with viral vectors that are non-replicating, non-integrating, and have no known potential for latency and re-activation should be followed for approximately 5 years post-treatment. The aim of this study (GT-ORACLE) is to evaluate ...

GO TO STUDY

Surgery remains the best option for the cure of patients with lung cancer. Around 7000 people in the UK undergo lung surgery each year, but up to 45% of patients developed post-operative complications leading to readmission to hospital and potentially poorer quality of life. National and international cancer, surgery and nutrition guidelines recommend a combination of exercise and nutritional support before and after surgery to help reduce post-operative complications. However it is not clear what is the best way to ...

GO TO STUDY